DocDollars

Tarsus Pharmaceuticals, Inc.

CA · United States · Reporting entity ID 100001448294

Total reported 2019–2025
$15.8M
#378 of 2,960 reporting companies — 0% of all reported industry payments
$11.7M in general payments across 82,653 records, plus $4.12M in research funding across 183 records.

How it breaks down

General payments $11,672,122
Research funding $4,124,058

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Tarsus Pharmaceuticals, Inc. reported $15.8M to US doctors and teaching hospitals from 2019 to 2025, ranking #378 of 2,960 reporting companies. 26% of that was research funding and 74% general payments such as consulting, speaking, food and travel. 82,653 general payment records and 183 research records were filed.

Common questions about Tarsus Pharmaceuticals, Inc.

How much has Tarsus Pharmaceuticals, Inc. paid US doctors?

Tarsus Pharmaceuticals, Inc. reported $15,796,180 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $11,672,122 in general payments, $4,124,058 in research funding.

How does Tarsus Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #378 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Tarsus Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.